Merus NV ((MRUS)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Merus N.V. is conducting a Phase 1/2 study titled ‘Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors.’ The study aims to determine the maximum tolerated dose and recommended Phase 2 dose of MCLA-129, either alone or in combination with other treatments, in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. This research is significant as it targets patients who are treatment-naïve or have progressed after prior therapies.
The intervention being tested is MCLA-129, a bispecific antibody targeting EGFR and c-MET, administered via intravenous infusion. In some cases, it is combined with Osimertinib or chemotherapy to enhance treatment efficacy.
The study follows a non-randomized, parallel assignment model with no masking, focusing primarily on treatment. This design allows for a clear assessment of MCLA-129’s effects in various patient groups.
The study began on April 28, 2021, with the primary completion and estimated study completion dates yet to be updated. The latest update was submitted on June 23, 2025, indicating ongoing progress.
This study update could positively influence Merus N.V.’s stock performance by showcasing potential advancements in cancer treatment, which may attract investor interest. It also positions Merus competitively in the oncology sector, where innovation is crucial.
The study is currently recruiting, with further details available on the ClinicalTrials portal.